Peter Kiener - Mar 23, 2023 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Peter Kiener by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Mar 23, 2023
Transactions value $
-$2,895
Form type
4
Date filed
3/27/2023, 04:05 PM
Previous filing
Jan 5, 2023
Next filing
Jun 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise $27.7K +9.68K $2.86 9.68K Mar 23, 2023 Direct
transaction CUE Common Stock Sale -$30.6K -9.33K -96.31% $3.28 357 Mar 23, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Options Exercise $0 -9.68K -9.16% $0.00 96.1K Mar 23, 2023 Common Stock 9.68K $2.86 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale to cover exercise price of cashless exercise of stock option.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 This Stock Option became exercisable in five equal annual installments beginning March 23, 2017 and is fully vested. This stock option expired on March 23, 2023.